Table of Contents Author Guidelines Submit a Manuscript
International Journal of Alzheimer's Disease
Volume 2010, Article ID 140539, 17 pages
Research Article

Alzheimer's Disease: A Pathogenetic Autoimmune Disorder Caused by Herpes Simplex in a Gene-Dependent Manner

Polygenic Pathways, Flat 4, 20 Upper Maze Hill, Saint Leonard's on Sea, East Sussex TN38 OLG, UK

Received 23 July 2010; Revised 27 September 2010; Accepted 22 October 2010

Academic Editor: Paula Moreira

Copyright © 2010 C. J. Carter. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Herpes simplex is implicated in Alzheimer's disease and viral infection produces Alzheimer's disease like pathology in mice. The virus expresses proteins containing short contiguous amino acid stretches (5–9aa “vatches” = viralmatches) homologous to APOE4, clusterin, PICALM, and complement receptor 1, and to over 100 other gene products relevant to Alzheimer's disease, which are also homologous to proteins expressed by other pathogens implicated in Alzheimer's disease. Such homology, reiterated at the DNA level, suggests that gene association studies have been tracking infection, as well as identifying key genes, demonstrating a role for pathogens as causative agents. Vatches may interfere with the function of their human counterparts, acting as dummy ligands, decoy receptors, or via interactome interference. They are often immunogenic, and antibodies generated in response to infection may target their human counterparts, producing protein knockdown, or generating autoimmune responses that may kill the neurones in which the human homologue resides, a scenario supported by immune activation in Alzheimer's disease. These data may classify Alzheimer's disease as an autoimmune disorder created by pathogen mimicry of key Alzheimer's disease-related proteins. It may well be prevented by vaccination and regular pathogen detection and elimination, and perhaps stemmed by immunosuppression or antibody adsorption-related therapies.

1. Introduction

Herpes simplex infection (HSV-1) has been shown to be a risk factor in Alzheimer’s disease; acting in synergy with possession of the APOE4 allele HSV-1 infection in mice or neuroblastoma cells increases beta-amyloid deposition and phosphorylation of the microtubule protein tau [15]. Viral infection in mice also results in hippocampal and entorhinal cortex neuronal degeneration, brain shrinkage, and memory loss, all as found in Alzheimer’s disease [6]. A recent study has also shown that anti-HSV-1 immunoglobulin M seropositivity, a marker of primary viral infection or reactivation, in a cohort of healthy patients, was significantly associated with the subsequent development of Alzheimer’s disease. Anti-HSV-1 IgG, a marker of lifelong infection, showed no association with subsequent Alzheimer’s disease development [7]. All of these factors support a viral influence on the development of Alzheimer’s disease. As shown below, proteins expressed by HSV-1 are homologous to all of the protein products of the major susceptibility gene in Alzheimer’s disease (APOE, clusterin, complement receptor 1, and PICALM) as well as to APP and tau and over 100 others implicated in genetic association studies. This suggests that Alzheimer’s disease is a “pathogenetic” disorder caused by HSV-1 (and other infections) that mimic these key susceptibility targets.

2. Methods

The Human herpesvirus 1 genome (NC_001798) was screened against the human proteome using the NCBI BLAST server with and without the Entrez Query filters (“Alzheimer” or “cholesterol”) [8]. Each BLAST returns a large list of human proteins, many of which display homology to several different HSV-1 proteins. A Tag cloud generator was used to quantify these different interactions This generates tags whose font size is proportional to the number of viral protein hits per human protein. The tag size scale was set from 1 to 20. Antigenicity (B cell epitope prediction) was predicted using the BepiPred server [9] at and T cell epitopes predicted using the Immune epitope database resource at  [10]. The immunogenicity index for individual amino acids is shown in Table 1. References for genetic association studies can be found at References for herpes simplex host viral interactions can be found in a database at Protein kinases phosphorylating the microtubule protein tau were identified from the Kinasource database at and from the material available at the ENTREZ gene interaction section for tau (MAPT).

Table 1: The antigenicity index (B cell epitope) for single amino acids defined by the BepiPred server. The top 6 scoring amino acids are highlighted in grey in the various tables.

Because of the large volume of data generated by the BLASTs, raw BLAST data have been made available at This survey is restricted to the herpes simplex virus, HSV-1, but similar data were obtained for other viral or pathogen species implicated in Alzheimer’s disease, where similar conclusions apply. These BLAST files and a summary of the results are available on the PolygenicPathways website at

3. Results

The results of the HSV-1 BLASTS, sized according to the number of viral hits per protein, using the filter “Alzheimer,” are shown in Table 2. Over a hundred human gene products, including all of the major Alzheimer’s disease susceptibility gene products (APOE4, clusterin, complement receptor 1, and PICALM) and most of many other diverse genes that have been implicated in Alzheimer’s disease in genetic association studies contain intraprotein sequences that are identical to those within herpes simplex viral proteins. The alignment with complement receptor 1 (CR1) has functional consequences, as glycoprotein C of the virus acts as a CR1 mimic, binding to other complement components (C3 and its derivatives) blocking the complement cascades and preventing formation of the membrane attack complex [12, 13]. This nicely illustrates one of the functional consequences of this type of mimicry.

Table 2: Human proteins with homology to HSV-1 proteins: The size of symbol (HUGO Nomenclature approved gene symbols) is proportional to the number of viral proteins displaying homology to the gene product. Filter “Alzheimer”: all of the genes encoding for these proteins with the exception of those with the strikethrough have been implicated in Alzheimer’s disease in genetic association studies. Filter “cholesterol”: genes encoding for proteins products in dashed boxes have been implicated in Alzheimer’s disease in genetic association studies. No Filter: HSV-1 proteins are most homologous to diverse families of kinases: Those boxed have been shown to phosphorylate the microtubule protein tau (Data from Kinasource and from NCBI Interactions section for the MAPT gene (tau)).

The type of viral homology for various different protein classes is shown in Table 3. These classes include products involved in APP signalling and processing (BACE1 and 2 and gamma-secretase components), cholesterol and lipoprotein function, tau function, inflammation, and oxidative stress, all of which are key processes disrupted in the Alzheimer’s disease brain.

Table 3: Major susceptibility gene products and members of other key signalling networks in Alzheimer’s disease (Sbjct) aligning with the translated HSV-1 genome (Query). The 6 amino acids with the highest B cell antigenicity index are highlighted in grey (see Table 1). Spaces denote a nonidentical amino acid; dashes represent gaps and + = conserved amino acid (similar physicochemical properties).

Using the filter “cholesterol,” a number of cholesterol and lipoprotein-related proteins again contain numerous sequences corresponding to those found in herpes viral proteins. This group of proteins play an important role in Alzheimer’s disease pathophysiology [1417].

The unfiltered BLAST returns the human proteins with the greatest homology to viral proteins and showed that herpes simplex viral proteins are highly homologous to a series of family members of diverse protein kinases. Several of these are known to phosphorylate the microtubule protein tau, an effect that is observed following HSV-1 infection [5]. The homology is such as to suggest that such phosphorylation may be accomplished by the viral proteins themselves, as well as by human protein kinases (Table 4).

Table 4: Alignment of the HSV-1 translated genome (Query) with 3 protein kinases known to phosphorylate tau (Sbjct). Glycogen synthase kinase GSK3A aligns with the same amino acids as GSK3B. CAMK2B: calcium/calmodulin-dependent protein kinase II beta. MAPK1: mitogen-activated protein kinase 1 (erk2).

This type of mimicry is by no means restricted to the herpes simplex virus as APOE4, clusterin, complement receptor 1, and PICALM are homologous to proteins from a diverse array of phages and viruses including phages that affect commensal bacteria, the influenza virus, and the HHV-6 virus which has a seroprevalence approaching 100% [18] (Table 5). Because of the universality of the phenomenon of viral matches within the human proteome, most proteins will be homologous to proteins from specific subsets of viruses. Viruses and other pathogens expressing proteins with homology to key susceptibility gene products might however be considered as important potential environmental risk factors. For the major Alzheimer’s disease gene candidates, several herpes species other than HSV-1 (HSV-2, 3, 6, 6B, and 8) fall into this category (Table 5).

Table 5: Other viruses expressing homologous proteins for the four major Alzheimer’s disease susceptibility gene products.

The tables in supplementary data on the website show that numerous Alzheimer’s disease susceptibility gene products are also homologous to proteins expressed by other pathogen risk factors in Alzheimer’s disease, including Chlamydia pneumonia, which has recently been detected in the Alzheimer’s disease brain [19].

Cryptococcus neoformans, Helicobacter pylori, Porphyromonas gingivalis (one cause of the gum disease that is a risk factor in Alzheimer’s disease [20]), Borrelia Burgdorferi, [21], Human herpesvirus 6, and Human herpesvirus 5 (Cytomegalovirus) [22].

Cryptococcus neoformans infection has been shown to be associated with a rare but curable form of dementia in two separate studies, where both patients had been consigned to healthcare for 3 years, with a diagnosis of Alzheimer’s disease. Both recovered normal function following antifungal treatment [23, 24]. Heliocobacter pylori eradication has also been reported to improve cognitive function in Alzheimer’s disease [25].

The protein sequences highlighted in grey in Table 3 contain strings of herpes simplex proteins that have been shown to bind to several interactome partners of tau [11] (see and are those most likely to form epitopes that cross-react with their human counterparts (Table 1). These include APOE4, complement receptor 1, clusterin, insulin degrading enzyme, the APP homologue, APLP2, the APP binding protein APBBI1P, the collagen amyloid plaque component CLAC, synuclein, and the foetal Alzheimer antigen, ALZ50. Tau appears to be highly antigenic (Table 2).

This antigenicity was further studied for the two key proteins in Alzheimer’s disease, beta-amyloid and tau, and the predicted immune epitopes compared with the HSV-1 viral proteins aligning within these various regions (Figures 2 and 3).

4. Vatches within Beta-Amyloid and the Microtubule Protein tau

Vatches (= viralmatches) are short contiguous amino acid stretches that are identical in viral and human proteins [26, 27]. There are several million within the human proteome, derived from evolutionary descent and from the insertion of multiple viruses into the human genome over millions of years. This type of insertion is not restricted to retroviruses, as herpes viruses, hepatitis viruses, influenza and the common cold virus, the coronavirus, and the papillomavirus, among others, have all been inserted into different genomic regions or are homologous to the encoded protein products. This has occurred on several occasions during evolutionary time, and these reinsertions appear to be responsible for the creation of gene families (see, where over 2 million such alignments are available for multiple viral species. In effect, the entire human genome appears to be composed of viral DNA. For example, the coverage of human chromosome 10 is complete, with 119,867 human/viral DNA matches.

A single HSV-1 vatch, translated back to DNA, is identical to DNA in 103 different genomic regions covering several human chromosomes. This phenomenon is likely responsible for the creation of gene families, and the HSV-1 virus appears to have been partly responsible for the creation of lipoprotein receptor families (Figure 1), and of numerous kinases within a number of different families (see above and Table 2). Over millions of years, these DNA inserts have been extensively shuffled by recombination, but millions of consecutive sequences are retained that encode for the viral matching protein components.

Figure 1: The BLAST result for HSV-1 proteins (translated viral genome versus human proteins) using the filter “lipoprotein.” The repetitive patterns in the pictogram reflect homology with a number of different lipoprotein receptors located on different chromosomes, as shown in the table.
Figure 2: The B cell and T cell immunogenicity profile for the beta-amyloid peptide. According to the servers, antigenicity values of >0.35 (B cell) or 0.5 (T cell) are considered immunogenic. The sequences of herpes simplex viral proteins that align with beta-amyloid are shown. Space: non-identical amino acid; +: conserved amino acid with similar physicochemical properties. Viruses and phages containing the VGGVV sequence, which has been used as an epitope to label beta-amyloid in Alzheimer’s disease, are also shown.
Figure 3: The B cell and T cell immunogenicity profile for the tau protein. The sequences of herpes simplex viral proteins that align with tau are shown. Space: non-identical amino acid; +: conserved amino acid with similar physicochemical properties.

Some of the vatches within beta-amyloid and tau are illustrated in Figures 2 and 3 which also demonstrates the B cell and T cell antigenicity of these proteins. As can be seen, there are numerous HSV-1 vatches within both proteins, many of which correspond to highly antigenic regions of APP or tau, and therefore also of the HSV-1 proteins.

In addition to the herpes simplex virus, a large number of other viruses express proteins containing a VGGVV sequence that is identical to that of a C-terminus peptide within beta-amyloid. Although not the most immunogenic of sequences, this epitope has been used to label beta-amyloid in Alzheimer’s disease brain [28] (Figure 2).

5. HSV-1 Proteins Bind to the Interaction Partners of tau

Because HSV-1 proteins are homologous to portions of the tau protein, one might expect the viral proteins to interfere with tau binding partners. This is indeed the case, as diverse herpes simplex viral proteins have been shown to bind to several of the interactome partners of tau (Table 6).

Table 6: The binding partners of tau (from the interaction section of NCBI gene) and their interaction with herpes simplex proteins (from the Wikigenes database) [11];

6. Discussion

Almost without exception, the genes encoding the proteins that match HSV-1 sequences (using the filter “Alzheimer”) have been reported as genetic risk factors in Alzheimer’s disease (see suggesting that such studies have been tracking HSV-1 (and other) infections over the years and inadvertently demonstrating that HSV-1 causes Alzheimer’s disease. This in no way detracts from the importance of these studies, but reflects a phenomenon that is probably common to most diseases. Because of our likely evolutionary descent from viruses, first opined by J.B.S. Haldane and Francois D’Herelle almost a century ago [29, 30], our genomes contain traces of this descent which are transcribed into these short contiguous amino acid stretches (vatches) that exactly match many of the proteins in the current virome. Repeated viral insertions also add several genes to the human genome at once, a phenomenon that is likely responsible for evolutionary jumps, as suggested by others [31]. The idea that higher forms of life originated from viruses, although contentious, is supported by the fact that the entire human genome appears to be comprised of viral DNA. For example a BLAST of human chromosome 10 against all viral genomes (DNA versus DNA) returned 119,867 hits, covering the entire chromosome, with no gaps, in both inter- and intragenic regions (see Similar results were obtained for other chromosomes. Our genomes and polymorphisms thus determine which vatches we possess, which viruses pose the threat, and which viral-related disease we are likely to develop. Whether we develop the disease in question will depend on our encounters with the virus, whether we are vaccinated, and no doubt on our HLA-antigens and immune background related to the elimination of self-antibodies soon after birth.

This phenomenon appears to be universal, as vatches have been found in the XMRV virus, relating to human proteins involved in mitochondrial respiration and prostate cancer, in the Epstein-Barr virus, which matches multiple sclerosis autoantigens [27], in the AIDS virus which targets vatches in over 50 components of the human immune network, in the papillomavirus which targets cervical cancer oncogenes, and in the HSV-2 virus which targets schizophrenia susceptibility gene products (see It is even relevant to human genetic diseases as the polyglutamine repeats observed in Huntington’s disease and spinocerebellar ataxias align with very common viruses (the ubiquitous HHV-6) while the cystic fibrosis mutant aligns with pseudomonas and staphylococcal phages, whose bacterial hosts have been found to shorten the lifespan of these patients. The London mutation in Alzheimer’s disease converts the surrounding peptide to a vatch that is homologous to proteins from the rhinoviruses that cause the common cold [26, 27, 32, 33]. Every human protein so far screened by the author, without a single exception, displays this type of homology to particular but specific sets of virus for each protein. Similarly all viruses so far screened (~30) express proteins with homology to a large but specific subset of human proteins.

These viral homologues may interfere with Alzheimer’s disease pathological pathways in a number of ways. Firstly, as demonstrated by the complement receptor 1 HSV-1 viral mimic, the viral protein can substitute for its human counterpart, presumably diverting its function towards different compartments. Secondly, as they are clearly able to substitute for their human counterparts, they are likely to interfere with their protein/protein networks (interactome). This was clearly demonstrated for tau, where herpes simplex virus proteins do indeed bind to tau binding partners.

As many of these matching sequences are highly immunogenic, antibodies to the virus may also target the human homologue, in effect producing a protein knockdown and reproducing the effects, but on a massive scale, seen in various Alzheimer’s disease-related knockout mice [3439]. Such immunogenic viral proteins may also generate antibodies capable of mounting an immune attack against their human counterparts, killing the cells in which they reside by immune and inflammatory mechanisms, and by complement-related lysis (see below).

7. The Dangers of Autoimmunity

The immunogenic profile of some of these homologues may also be responsible for the neurodegeneration and pathological features observed in Alzheimer’s disease. Antibodies to the human proteins may result in immune, inflammation, and complement pathway activation, killing the cells in which the human homologue resides. There is a great deal of evidence supporting autoimmune attack in the Alzheimer’s disease brain.

A number of immune-system-related proteins are found in amyloid plaques or neurofibrillary tangles. Interleukin 1 alpha, interleukin 6, and tumour necrosis factor are all been localised within plaques, and acute phase proteins involved in inflammation, such as amyloid P, alpha-1 antichymotrypsin, and C-reactive protein are also plaque components while immunoglobulin G is located in the plaque corona [14, 4042]. Large increases in IgG levels have been recorded in the brain parenchyma, in apoptotic dying neurones, and in cerebral blood vessels in the Alzheimer’s disease brain [43]. Complement component C3 is found in Alzheimer’s disease amyloid plaques along with complement C4 [44]. Complement components Clq, C3d, and C4d are present in plaques, dystrophic neuritis, and neurofibrillary tangles [45].

The membrane attack complex (MAC), composed of complement proteins C5 to C9, forms a channel that is inserted into the membranes of pathogens, destroying them by lysis. These components cannot be detected in temporal cortex amyloid plaques in Alzheimer’s disease [41, 44, 46]. However the MAC complex is present in dystrophic neurites and neurofibrillary tangles [45], and others have detected this complex in neuritic plaques and tangles, along with deposition of C1q, C3, and clusterin [47]. The membrane attack complex has also been detected in the neuronal cytoplasm in AD brains and associated with neurofibrillary tangles and lysosomes [46].The presence of the MAC complex in neurones might suggest that neuronal lysis by the MAC complex could contribute to neuronal cell death [45].

The microtubule protein tau was one of the more antigenic proteins revealed in this survey and one with numerous matches to herpes viral proteins that would be equally immunogenic. Immunisation with tau in mice produces tauopathy, neurofibrillary tangles, axonal damage, and gliosis [48] demonstrating the dangers of autoimmunity in a manner directly relevant to Alzheimer’s disease.

Beta-amyloid autoantibodies are common in the ageing population and in Alzheimer’s disease and may be related to herpes simplex and numerous other viruses or phage proteins that exactly vatch a VGGVV C-terminal sequence in beta-amyloid that is immunogenic. The epitope for this sequence labels beta-amyloid in the Alzheimer’s brain [28]. This pentapeptide is, per se, fibrillogenic [49]. This is a characteristic of both beta-amyloid and of HSV-1 glycoprotein B peptide fragments containing this sequence. The viral glycoprotein B fragments form thioflavin T positive fibrils which accelerate beta-amyloid fibril formation and are neurotoxic in cell culture [50]. Other stretches of beta-amyloid are homologous to a diverse set of viral, bacterial, fungal, and allergenic proteins, likely providing the source of the autoantibodies in the ageing population [32].

Antibodies to beta-amyloid have been suggested as a therapeutic option in Alzheimer’s disease. The potential use of beta-amyloid antibodies is based on their ability to reduce plaque burden and neurite dystrophy in APP transgenic mice [51]. Several studies have demonstrated that beta-amyloid antibodies reduce plaque burden in APP transgenic models and that they can also improve cognitive performance [52]. However amyloid antibodies extracted from the serum of old APP transgenic mice potentiate the toxicity of beta-amyloid, and Alzheimer’s disease patients display an enhanced immune response to the peptide [53]. Again in transgenic mice, different immune backgrounds can influence the type of immune responses elicited by beta-amyloid. For example, B and T cell responses to beta-amyloid can be modified in HLA-DR3, -DR4, -DQ6, or -DQ8 transgenic mice [54]. HLA-antigen diversity in Man is also likely to determine the outcome of beta-amyloid/antibody interactions. A large number of Alzheimer’s disease susceptibility gene candidates, including clusterin and complement receptor 1, as well as diverse interleukins and other cytokines, C reactive protein, HLA-antigens, Fc epsilon and Toll receptors, and the viral-activated kinase PKR, are intimately concerned with pathogen defence and or the immune system, supporting a genetic contribution to the immune pathogenesis of Alzheimer’s disease (see

Beta-amyloid vaccination in Alzheimer’s disease (against Abeta1-42) has so far not been successful and sadly resulted in meningoencephalitis and the death of a patient [55]. While certain beta-amyloid antibodies may reduce plaque burden, there is an evident risk that they may also trigger an autoimmune response, potentially killing beta-amyloid containing neurones. Catalytic autoantibodies are less able to form stable immune complexes and likely represent the safest way forward in this area [56, 57]. Given the homology of beta-amyloid to so many viruses and the potential dangers of autoimmunity, as well as the clearly toxic effects of tau immunisation, the pursuit of clinical trials with beta-amyloid antibodies, with the exception of catalytic forms, must surely be questioned.

8. Conclusions

Alzheimer’s disease proteins encoded by all of the major genetic players in Alzheimer’s disease and many other relevant proteins are homologous to proteins from the herpes simplex virus, confirming the implication of this virus as a causative agent in this disease [48, 50, 5870]. Because of homology to other viruses and pathogens, these too may be implicated. These include HHV-6, the cytomegalovirus, Borrelia, Burgdorferi, Chlamydia Pneumoniae, Helicobacter pylori, Cryptococcus neoformans and bacteria promoting gum disease, such as P. Gingivalis, all of which also express proteins homologous to the products of numerous Alzheimer’s disease susceptibility genes (see

No vaccine against HSV-1 exists, but in the long term, may perhaps be able to prevent Alzheimer’s disease, although the potential dangers of vaccine-related autoimmunity evidently need to be addressed. Interestingly, cancer-causing viruses including the Epstein-Barr-virus, hepatitis b, and the papillomavirus align with the peptide stretch within beta-amyloid [32] that is cleaved by the beneficial catalytic autoantibodies to beta-amyloid [56, 57]. Cancer is inversely associated with the risk of developing Alzheimer’s disease [71, 72]. As a vaccine to the human papillomavirus already exists to prevent cervical cancer [73], it may well have a role to play in the prevention or therapy of Alzheimer’s disease, again with due regard to the problem of vaccine-related autoimmunity. Alternatively, immunisation with this beneficial region of the beta-amyloid peptide might be considered as a viable therapeutic option.

Many of the toxic effects of HSV-1 infection are likely to be related to autoimmunity, caused by antibodies to the viral proteins that also target their human counterparts. In this case, it is possible that immunosuppressant therapy may be of benefit in Alzheimer’s disease patients and also that aggressive antiviral therapy should be pursued. Immunoadsorption of tau and beta-amyloid antibodies, a technique used to good effect in certain patients with myasthenia gravis (characterised by autoantibodies to nicotinic receptors) [74] may also be of benefit. As other pathogens may also demonstrate this type of mimicry, detailed and regular pathogen screens in the ageing population and in the early stages of Alzheimer’s patients may also be of use.

Alzheimer’s disease thus appears to be one, probably of many, “pathogenetic” diseases, caused by viruses and other pathogens, but dependent on our genes, which dictate the protein sequences that match those in particular subsets of pathogen proteins. There are almost 3,000 viral genomes in the NCBI database, probably reflecting but a small proportion of those existing on the planet. In addition, as viruses regularly mutate with replication there are likely to be multiple strains of HSV-1 (and other viruses), only one of which is recorded in the NCBI database. Nevertheless, with current bioinformatics techniques, it should be possible to rapidly identify all vatches in the human proteome, to match them to particular viruses (and other pathogens, Bacteria, fungi, yeast, parasites, etc.), and to pair these with diverse human diseases. Our understanding of this universal phenomenon could radically change the face of therapy in a variety of human conditions.


  1. R. F. Itzhaki, C. B. Dobson, W.-R. Lin, and M. A. Wozniak, “Association of HSV1 and apolipoprotein E-ε4 in Alzheimer's disease,” Journal of NeuroVirology, vol. 7, no. 6, pp. 570–571, 2001. View at Publisher · View at Google Scholar · View at Scopus
  2. R. F. Itzhaki, C. B. Dobson, M. A. Wozniak et al., “Herpes simplex virus type 1 and Alzheimer's disease,” Annals of Neurology, vol. 55, no. 2, pp. 299–301, 2004. View at Google Scholar · View at Scopus
  3. R. F. Itzhaki and M. A. Wozniak, “Alzheimer's disease-like changes in herpes simplex virus type 1 infected cells: the case for antiviral therapy,” Rejuvenation Research, vol. 11, no. 2, pp. 319–320, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. M. A. Wozniak, R. F. Itzhaki, S. J. Shipley, and C. B. Dobson, “Herpes simplex virus infection causes cellular β-amyloid accumulation and secretase upregulation,” Neuroscience Letters, vol. 429, no. 2-3, pp. 95–100, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. M. A. Wozniak, A. L. Frost, and R. F. Itzhaki, “Alzheimer's disease-specific tau phosphorylation is induced by herpes simplex virus type 1,” Journal of Alzheimer's Disease, vol. 16, no. 2, pp. 341–350, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. A. G. Armien, S. Hu, M. R. Little et al., “Chronic cortical and subcortical pathology with associated neurological deficits ensuing experimental herpes encephalitis,” Brain Pathology, vol. 20, no. 4, pp. 738–750, 2010. View at Publisher · View at Google Scholar · View at PubMed
  7. L. Letenneur, K. Pérès, H. Fleury et al., “Seropositivity to herpes simplex virus antibodies and risk of Alzheimer's disease: a population-based cohort study,” PLoS ONE, vol. 3, no. 11, Article ID e3637, 2008. View at Publisher · View at Google Scholar · View at PubMed
  8. S. F. Altschul, T. L. Madden, A. A. Schäffer et al., “Gapped BLAST and PSI-BLAST: a new generation of protein database search programs,” Nucleic Acids Research, vol. 25, no. 17, pp. 3389–3402, 1997. View at Publisher · View at Google Scholar · View at Scopus
  9. J. E. Larsen, O. Lund, and M. Nielsen, “Improved method for predicting linear B-cell epitopes,” Immunome Research, vol. 2, article 2, 2006. View at Google Scholar
  10. M. Nielsen, C. Lundegaard, O. Lund, and C. Keşmir, “The role of the proteasome in generating cytotoxic T-cell epitopes: insights obtained from improved predictions of proteasomal cleavage,” Immunogenetics, vol. 57, no. 1-2, pp. 33–41, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. C. J. Carter, “Herpes simplex: host viral protein interactions,” WikiGenes. In press.
  12. H. P. Huemer, Y. Wang, P. Garred, V. Koistinen, and S. Oppermann, “Herpes simplex virus glycoprotein C: molecular mimicry of complement regulatory proteins by a viral protein,” Immunology, vol. 79, no. 4, pp. 639–647, 1993. View at Google Scholar
  13. R. Tal-Singer, C. Seidel-Dugan, L. Fries et al., “Herpes simplex virus glycoprotein C is a receptor for complement component iC3b,” Journal of Infectious Diseases, vol. 164, no. 4, pp. 750–753, 1991. View at Google Scholar
  14. C. J. Carter, “Convergence of genes implicated in Alzheimer's disease on the cerebral cholesterol shuttle: APP, cholesterol, lipoproteins, and atherosclerosis,” Neurochemistry International, vol. 50, no. 1, pp. 12–38, 2007. View at Publisher · View at Google Scholar · View at PubMed
  15. S. Jaeger and C. U. Pietrzik, “Functional role of lipoprotein receptors in Alzheimer's disease,” Current Alzheimer Research, vol. 5, no. 1, pp. 15–25, 2008. View at Publisher · View at Google Scholar
  16. I. J. Martins, T. Berger, M. J. Sharman, G. Verdile, S. J. Fuller, and R. N. Martins, “Cholesterol metabolism and transport in the pathogenesis of Alzheimer's disease,” Journal of Neurochemistry, vol. 111, no. 6, pp. 1275–1308, 2009. View at Publisher · View at Google Scholar
  17. A. Papassotiropoulos, M. A. Wollmer, M. Tsolaki et al., “A cluster of cholesterol-related genes confers susceptibility for Alzheimer's disease,” Journal of Clinical Psychiatry, vol. 66, no. 7, pp. 940–947, 2005. View at Google Scholar
  18. G. Campadelli-Fiume, P. Mirandola, and L. Menotti, “Human herpesvirus 6: an emerging pathogen,” Emerging Infectious Diseases, vol. 5, no. 3, pp. 353–366, 1999. View at Google Scholar
  19. C. J. Hammond, L. R. Hallock, R. J. Howanski, D. M. Appelt, C. S. Little, and B. J. Balin, “Immunohistological detection of Chlamydia pneumoniae in the Alzheimer's disease brain,” BMC Neuroscience, vol. 11, article 121, 2010. View at Publisher · View at Google Scholar · View at PubMed
  20. P. S. Stein, M. Desrosiers, S. J. Donegan, J. F. Yepes, and R. J. Kryscio, “Tooth loss, dementia and neuropathology in the Nun Study,” Journal of the American Dental Association, vol. 138, no. 10, pp. 1314–1322, 2007. View at Google Scholar
  21. J. Miklossy, K. Khalili, L. Gern et al., “Borrelia burgdorferi persists in the brain in chronic lyme neuroborreliosis and may be associated with Alzheimer disease,” Journal of Alzheimer's Disease, vol. 6, no. 6, pp. 639–649, 2004. View at Google Scholar
  22. W. R. Lin, M. A. Wozniak, R. J. Cooper, J. K. Wilcock, and R. F. Itzhaki, “Herpesviruses in brain and Alzheimer's disease,” Journal of Pathology, vol. 197, no. 3, pp. 395–402, 2002. View at Publisher · View at Google Scholar · View at PubMed
  23. T. A. Ala, R. C. Doss, and C. J. Sullivan, “Reversible dementia: a case of cryptococcal meningitis masquerading as Alzheimer's disease,” Journal of Alzheimer's Disease, vol. 6, no. 5, pp. 503–508, 2004. View at Google Scholar
  24. M. Hoffmann, J. Muniz, E. Carroll, and J. De Villasante, “Cryptococcal meningitis misdiagnosed as alzheimer's disease: complete neurological and cognitive recovery with treatment,” Journal of Alzheimer's Disease, vol. 16, no. 3, pp. 517–520, 2009. View at Publisher · View at Google Scholar · View at PubMed
  25. J. Kountouras, M. Boziki, E. Gavalas et al., “Eradication of Helicobacter pylori may be beneficial in the management of Alzheimer's disease,” Journal of Neurology, vol. 256, no. 5, pp. 758–767, 2009. View at Publisher · View at Google Scholar · View at PubMed
  26. C. J Carter, “Proteins of the XMRV retrovirus implicated in chronic fatigue syndrome and prostate cancer are homologous to human proteins relevant to both diseases,” Nature Precedings. In press. View at Publisher · View at Google Scholar
  27. C. J. Carter, “Extensive Viral mimicry of human proteins in AIDS, autoimmune disorders, late-onset and familial Alzheimer;s disease and other genetic diseases,” Nature Precedings. In press.
  28. C. Schwab, H. Akiyama, E. G. McGeer, and P. L. McGeer, “Extracellular neurofibrillary tangles are immunopositive for the 40 carboxy-terminal sequence of β-amyloid protein,” Journal of Neuropathology and Experimental Neurology, vol. 57, no. 12, pp. 1131–1137, 1998. View at Google Scholar
  29. J. B. S. Haldane, “The origin of life,” Rationalist Annual, vol. 148, pp. 3–10, 1988. View at Google Scholar
  30. F. D'Herelle, The Bacteriophage; Its Role in Immunity, Masson et Cie, Paris, France, 1922.
  31. K. Khodosevich, Y. Lebedev, and E. Sverdlov, “Endogenous retroviruses and human evolution,” Comparative and Functional Genomics, vol. 3, no. 6, pp. 494–498, 2002. View at Publisher · View at Google Scholar · View at PubMed
  32. C. J. Carter, “Familial and late-onset Alzheimer's disease: autoimmune disorders triggered by viral, microbial and allergen mimics of beta-amyloid and APP mutants ?” Nature Precedings. In press.
  33. C. J. Carter, “The human genome is composed of viral DNA: Viral homologues of the protein products cause Alzheimer's disease and others via autoimmune mechanisms,” Nature Precedings. In press.
  34. G. R. Seabrook and T. W. Rosahl, “Transgenic animals relevant to Alzheimer's disease,” Neuropharmacology, vol. 38, no. 1, pp. 1–17, 1999. View at Publisher · View at Google Scholar
  35. Y. Senechal, P. H. Kelly, J. F. Cryan, F. Natt, and K. K. Dev, “Amyloid precursor protein knockdown by siRNA impairs spontaneous alternation in adult mice,” Journal of Neurochemistry, vol. 102, no. 6, pp. 1928–1940, 2007. View at Publisher · View at Google Scholar · View at PubMed
  36. T. L. Spires and B. T. Hyman, “Transgenic models of Alzheimer's disease: learning from animals,” NeuroRx, vol. 2, no. 3, pp. 423–437, 2005. View at Publisher · View at Google Scholar
  37. D.-L. Zhang, Y.-Q. Chen, X. Jiang, T.-T. Ji, and B. Mei, “Oxidative damage increased in presenilin1/presenilin2 conditional double knockout mice,” Neuroscience Bulletin, vol. 25, no. 3, pp. 131–137, 2009. View at Publisher · View at Google Scholar
  38. M. Hiltunen, T. Van Groen, and J. Jolkkonen, “Functional roles of amyloid-β protein precursor and amyloid-β peptides: evidence from experimental studies,” Journal of Alzheimer's Disease, vol. 18, no. 2, pp. 401–412, 2009. View at Publisher · View at Google Scholar · View at PubMed
  39. D. Langui, F. Lachapelle, and C. Duyckaerts, “Animal models of neurodegenerative diseases,” Medecine/Sciences, vol. 23, no. 2, pp. 180–186, 2007. View at Google Scholar
  40. P. Eikelenboom, E. Van Exel, J. J.M. Hoozemans, R. Veerhuis, A. J.M. Rozemuller, and W. A. Van Gool, “Neuroinflammation—an early event in both the history and pathogenesis of Alzheimer's disease,” Neurodegenerative Diseases, vol. 7, no. 1–3, pp. 38–41, 2010. View at Publisher · View at Google Scholar · View at PubMed
  41. R. Veerhuis, I. Janssen, C. E. Hack, and P. Eikelenboom, “Early complement components in Alzheimer's disease brains,” Acta Neuropathologica, vol. 91, no. 1, pp. 53–60, 1996. View at Publisher · View at Google Scholar
  42. R. Veerhuis, I. Janssen, C. J. A. De Groot, F. L. Van Muiswinkel, C. E. Hack, and P. Eikelenboom, “Cytokines associated with amyloid plaques in Alzheimer's disease brain stimulate human glial and neuronal cell cultures to secrete early complement proteins, but not C1-inhibitor,” Experimental Neurology, vol. 160, no. 1, pp. 289–299, 1999. View at Publisher · View at Google Scholar · View at PubMed
  43. M. R. D'Andrea, “Evidence linking neuronal cell death to autoimmunity in Alzheimer's disease,” Brain Research, vol. 982, no. 1, pp. 19–30, 2003. View at Publisher · View at Google Scholar
  44. R. Veerhuis, P. Van der Valk, I. Janssen, S. S. Zhan, W. E. Van Nostrand, and P. Eikelenboom, “Complement activation in amyloid plaques in Alzheimer's disease brains does not proceed further than C3,” Virchows Archiv, vol. 426, no. 6, pp. 603–610, 1995. View at Google Scholar
  45. P. L. McGeer, H. Akiyama, S. Itagaki, and E. G. McGeer, “Activation of the classical complement pathway in brain tissue of Alzheimer patients,” Neuroscience Letters, vol. 107, no. 1–3, pp. 341–346, 1989. View at Publisher · View at Google Scholar
  46. S. Itagaki, H. Akiyama, H. Saito, and P. L. McGeer, “Ultrastructural localization of complement membrane attack complex (MAC)-like immunoreactivity in brains of patients with Alzheimer's disease,” Brain Research, vol. 645, no. 1-2, pp. 78–84, 1994. View at Google Scholar · View at Scopus
  47. H. Zanjani, C. E. Finch, C. Kemper et al., “Complement activation in very early Alzheimer disease,” Alzheimer Disease and Associated Disorders, vol. 19, no. 2, pp. 55–66, 2005. View at Publisher · View at Google Scholar
  48. H. Rosenmann, N. Grigoriadis, D. Karussis et al., “Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein,” Archives of Neurology, vol. 63, no. 10, pp. 1459–1467, 2006. View at Publisher · View at Google Scholar · View at PubMed
  49. M. A. C. Morelli, M. DeBiasi, A. DeStradis, and A. M. Tamburro, “An aggregating elastin-like pentapeptide,” Journal of Biomolecular Structure and Dynamics, vol. 11, no. 1, pp. 181–190, 1993. View at Google Scholar
  50. D. H. Cribbs, B. Y. Azizeh, C. W. Cotman, and F. M. LaFerla, “Fibril formation and neurotoxicity by a herpes simplex virus glycoprotein B fragment with homology to the Alzheimer's Aβ peptide,” Biochemistry, vol. 39, no. 20, pp. 5988–5994, 2000. View at Publisher · View at Google Scholar
  51. D. Schenk, R. Barbour, W. Dunn et al., “Immunization with amyloid-β attenuates Alzheimer disease-like pathology in the PDAPP mouse,” Nature, vol. 400, no. 6740, pp. 173–177, 1999. View at Publisher · View at Google Scholar · View at PubMed
  52. S. Röskam, F. Neff, R. Schwarting, M. Bacher, and R. Dodel, “APP transgenic mice: the effect of active and passive immunotherapy in cognitive tasks,” Neuroscience and Biobehavioral Reviews, vol. 34, pp. 487–499, 2010. View at Publisher · View at Google Scholar · View at PubMed
  53. A. Nath, E. Hall, M. Tuzova et al., “Autoantibodies to amyloid β-peptide (Aβ) are increased in Alzheimer's disease patients and Aβ antibodies can enhance Aβ neurotoxicity: implications for disease pathogenesis and vaccine development,” NeuroMolecular Medicine, vol. 3, no. 1, pp. 29–39, 2003. View at Publisher · View at Google Scholar
  54. P. Das, S. Chapoval, V. Howard, C. S. David, and T. E. Golde, “Immune responses against Aβ1-42 in HLA class II transgenic mice: implications for Aβ1-42 immune-mediated therapies,” Neurobiology of Aging, vol. 24, no. 7, pp. 969–976, 2003. View at Publisher · View at Google Scholar
  55. I. Ferrer, M. Boada Rovira, M. L. Sánchez Guerra, M. J. Rey, and F. Costa-Jussá, “Neuropathology and pathogenesis of encephalitis following amyloid-β immunization in Alzheimer's disease,” Brain Pathology, vol. 14, no. 1, pp. 11–20, 2004. View at Google Scholar
  56. S. Paul, S. Planque, and Y. Nishiyama, “Immunological origin and functional properties of catalytic autoantibodies to amyloid β peptide,” Journal of Clinical Immunology, vol. 30, supplement 1, pp. S43–S49, 2010. View at Publisher · View at Google Scholar · View at PubMed
  57. H. Taguchi, S. Planque, G. Sapparapu et al., “Exceptional amyloid β peptide hydrolyzing activity of nonphysiological immunoglobulin variable domain scaffolds,” Journal of Biological Chemistry, vol. 283, no. 52, pp. 36724–36733, 2008. View at Publisher · View at Google Scholar · View at PubMed
  58. J. S. Burgos, C. Ramirez, I. Sastre, and F. Valdivieso, “Effect of apolipoprotein E on the cerebral load of latent herpes simplex virus type 1 DNA,” Journal of Virology, vol. 80, no. 11, pp. 5383–5387, 2006. View at Publisher · View at Google Scholar · View at PubMed
  59. C. J. Carter, “Interactions between the products of the Herpes simplex genome and Alzheimer's disease susceptibility genes: relevance to pathological-signalling cascades,” Neurochemistry International, vol. 52, no. 6, pp. 920–934, 2008. View at Publisher · View at Google Scholar · View at PubMed
  60. K. Honjo, R. van Reekum, and N. P. L. G. Verhoeff, “Alzheimer's disease and infection: do infectious agents contribute to progression of Alzheimer's disease?” Alzheimer's and Dementia, vol. 5, no. 4, pp. 348–360, 2009. View at Publisher · View at Google Scholar · View at PubMed
  61. R. Itzhaki, “Herpes simplex virus type 1, apolipoprotein E and alzheimer's disease,” Herpes, vol. 11, supplement 2, pp. 77A–82A, 2004. View at Google Scholar
  62. R. F. Itzhaki, W.-R. Lin, D. Shang, G. K. Wilcock, B. Faragher, and G. A. Jamieson, “Herpes simplex virus type 1 in brain and risk of Alzheimer's disease,” Lancet, vol. 349, no. 9047, pp. 241–244, 1997. View at Publisher · View at Google Scholar
  63. R. F. Itzhaki, M. A. Wozniak, D. M. Appelt, and B. J. Balin, “Infiltration of the brain by pathogens causes Alzheimer's disease,” Neurobiology of Aging, vol. 25, no. 5, pp. 619–627, 2004. View at Publisher · View at Google Scholar · View at PubMed
  64. I. Kuhlmann, A. M. Minihane, P. Huebbe, A. Nebel, and G. Rimbach, “Apolipoprotein e genotype and hepatitis C, HIV and herpes simplex disease risk: a literature review,” Lipids in Health and Disease, vol. 9, article 8, 2010. View at Publisher · View at Google Scholar · View at PubMed
  65. W.-R. Lin, D. Shang, and R. F. Itzhaki, “Neurotropic viruses and Alzheimer disease: interaction of herpes simplex type I virus and apolipoprotein E in the etiology of the disease,” Molecular and Chemical Neuropathology, vol. 28, no. 1–3, pp. 135–141, 1996. View at Google Scholar
  66. R. B. Pyles, “The association of herpes simplex virus and Alzheimer's disease: a potential synthesis of genetic and environmental factors,” Herpes, vol. 8, no. 3, pp. 64–68, 2001. View at Google Scholar
  67. M. A. Wozniak, S. J. Shipley, M. Combrinck, G. K. Wilcock, and R. F. Itzhaki, “Productive herpes simplex virus in brain of elderly normal subjects and Alzheimer's disease patients,” Journal of Medical Virology, vol. 75, no. 2, pp. 300–306, 2005. View at Publisher · View at Google Scholar · View at PubMed
  68. R. F. Itzhaki and M. A. Wozniak, “Herpes simplex virus type 1 in Alzheimer's disease: the enemy within,” Journal of Alzheimer's Disease, vol. 13, no. 4, pp. 393–405, 2008. View at Google Scholar
  69. I. Mori, Y. Kimura, H. Naiki et al., “Reactivation of HSV-1 in the brain of patients with familial Alzheimer's disease,” Journal of Medical Virology, vol. 73, no. 4, pp. 605–611, 2004. View at Publisher · View at Google Scholar · View at PubMed
  70. Á. Zambrano, L. Solis, N. Salvadores, M. Cortés, R. Lerchundi, and C. Otth, “Neuronal cytoskeletal dynamic modification and neurodegeneration induced by infection with herpes simplex virus type 1,” Journal of Alzheimer's Disease, vol. 14, no. 3, pp. 259–269, 2008. View at Google Scholar
  71. C. M. Roe, M. I. Behrens, C. Xiong, J. P. Miller, and J. C. Morris, “Alzheimer disease and cancer,” Neurology, vol. 64, no. 5, pp. 895–898, 2005. View at Google Scholar
  72. C. M. Roe, A. L. Fitzpatrick, C. Xiong et al., “Cancer linked to Alzheimer disease but not vascular dementia,” Neurology, vol. 74, no. 2, pp. 106–112, 2010. View at Publisher · View at Google Scholar · View at PubMed
  73. S. M. Garland and J. S. Smith, “Human papillomavirus vaccines: current status and future prospects,” Drugs, vol. 70, no. 9, pp. 1079–1098, 2010. View at Publisher · View at Google Scholar · View at PubMed
  74. S. Wagner, R. W.C. Janzen, C. Mohs, S. Pohlmann, R. Klingel, and P. W. Grützmacher, “Long-term treatment of refractory myasthenia gravis with immunoadsorption Langzeitbehandlung der therapierefraktären myasthenia gravis mittels immunadsorption,” Deutsche Medizinische Wochenschrift, vol. 133, no. 46, pp. 2377–2382, 2008. View at Publisher · View at Google Scholar · View at PubMed